Bristol-Myers Squibb Co (BMY) : Retirement Design Management Inc Adv reduced its stake in Bristol-Myers Squibb Co by 0.15% during the most recent quarter end. The investment management company now holds a total of 19,810 shares of Bristol-Myers Squibb Co which is valued at $985,944 after selling 30 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Bristol-Myers Squibb Co makes up approximately 0.62% of Retirement Design Management Inc Adv’s portfolio.
Other Hedge Funds, Including , National Pension Service boosted its stake in BMY in the latest quarter, The investment management firm added 81,955 additional shares and now holds a total of 1,018,161 shares of Bristol-Myers Squibb Co which is valued at $50,673,873. Bristol-Myers Squibb Co makes up approx 0.41% of National Pension Service’s portfolio.Waverton Investment Management Ltd reduced its stake in BMY by selling 18,506 shares or 1.99% in the most recent quarter. The Hedge Fund company now holds 912,768 shares of BMY which is valued at $45,227,654. Bristol-Myers Squibb Co makes up approx 3.06% of Waverton Investment Management Ltd’s portfolio.Ct Financial Advisors reduced its stake in BMY by selling 388 shares or 4.94% in the most recent quarter. The Hedge Fund company now holds 7,465 shares of BMY which is valued at $369,891. Bristol-Myers Squibb Co makes up approx 0.23% of Ct Financial Advisors’s portfolio.Kelman-lazarov boosted its stake in BMY in the latest quarter, The investment management firm added 145 additional shares and now holds a total of 803 shares of Bristol-Myers Squibb Co which is valued at $39,997. Bristol-Myers Squibb Co makes up approx 0.02% of Kelman-lazarov’s portfolio.Nadler Financial Group reduced its stake in BMY by selling 591 shares or 7.8% in the most recent quarter. The Hedge Fund company now holds 6,989 shares of BMY which is valued at $387,400. Bristol-Myers Squibb Co makes up approx 0.16% of Nadler Financial Group’s portfolio.
Bristol-Myers Squibb Co closed down -0.47 points or -0.94% at $49.77 with 1,38,48,384 shares getting traded on Friday. Post opening the session at $50.35, the shares hit an intraday low of $49.755 and an intraday high of $50.65 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Shares were Reiterated by Barclays on Sep 9, 2016 to “Equal Weight” and Lowered the Price Target to $ 65 from a previous price target of $75 .Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.